Sorrento Therapeutics (SRNE)
(Delayed Data from OTC)
$0.01 USD
-0.01 (-31.50%)
Updated Apr 26, 2024 03:54 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRNE 0.01 -0.01(-31.50%)
Will SRNE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SRNE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRNE
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
SRNE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sorrento Therapeutics (SRNE) Loses -77.24% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is AMN Healthcare Services (AMN) Stock Outpacing Its Medical Peers This Year?
ANI Pharmaceuticals (ANIP) Surpasses Q3 Earnings and Revenue Estimates
Other News for SRNE
Three new option listings on April 15th